Novo Nordisk

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial

Lilly’s pill underperformance prompted investor sell-off, triggering price cuts plus lawsuits by Novo Nordisk to protect its GLP-1 market lead.